Development and characterization of a stable eGFP enterovirus 71 for antiviral screening

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 198-205

  Shang, Baodi ^a   Deng, Chenglin ^a   Ye, Hanqing ^a   Xu, Wenbo ^b   Yuan, Zhiming ^a   Shi, Pei Yong ^c   Zhang, Bo ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b China Center for Disease Control and Prevention   (China)

^c WADSWORTH CENTER   (United States)

Author keywords

Antiviral drug discovery; Enterovirus; High throughput assay; Reporter virus

Indexed keywords

COMPLEMENTARY DNA; ENHANCED GREEN FLUORESCENT PROTEIN; PROTEIN VP4;

5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENTEROVIRUS 71; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS LOAD;

5' UNTRANSLATED REGIONS; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DRUG EVALUATION, PRECLINICAL; ENTEROVIRUS A, HUMAN; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; STAINING AND LABELING; VERO CELLS; VIRAL STRUCTURAL PROTEINS;

ENTEROVIRUS; HUMAN ENTEROVIRUS 71;

EID: 84872132019     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.010     Document Type: Article

References (29)

1. Baltera R.F., Tershak D.R. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J. Virol. 1989, 63:4441-4444.
2. Campagnola G., Gong P., Peersen O.B. High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. Antiviral Res. 2011, 91:241-251.
3. Chua K.B., Kasri A.R. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol. Sin. 2011, 26:221-228.
4. De Palma A.M., Thibaut H.J., van der Linden L., Lanke K., Heggermont W., Ireland S., Andrews R., Arimilli M., Al-Tel T.H., De Clercq E., van Kuppeveld F., Neyts J. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 2009, 53:1850-1857.
5. Dower K., Rubins K.H., Hensley L.E., Connor J.H. Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res. 2011, 91:72-80.
6. Falah N., Violot S., Decimo D., Berri F., Foucault-Grunenwald M.L., Ohlmann T., Schuffenecker I., Morfin F., Lina B., Riteau B., Cortay J.C. Ex vivo and in vivo inhibition of human rhinovirus replication by a new pseudosubstrate of viral 2A protease. J. Virol. 2012, 86:691-704.
7. Gong E., Ivens T., Van den Eynde C., Hallenberger S., Hertogs K. Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout. J. Virol. Methods 2008, 151:121-125.
8. Lee J.C., Shih S.R., Chang T.Y., Tseng H.Y., Shih Y.F., Yen K.J., Chen W.C., Shie J.J., Fang J.M., Liang P.H., Chao Y.S., Hsu J.T. A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal. Biochem. 2008, 375:115-123.
9. Liu Y., Wang C., Mueller S., Paul A.V., Wimmer E., Jiang P. Direct interaction between two viral proteins, the nonstructural protein 2C and the capsid protein VP3, is required for enterovirus morphogenesis. PLoS Pathog. 2010, 6:e1001066.
10. Lo M.K., Tilgner M., Shi P.Y. Potential high-throughput assay for screening inhibitors of West Nile virus replication. J. Virol. 2003, 77:12901-12906.
11. Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 2009, 15:794-797.
12. Paul A.V., Rieder E., Kim D.W., van Boom J.H., Wimmer E. Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. J. Virol. 2000, 74:10359-10370.
13. Pfister T., Wimmer E. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J. Biol. Chem. 1999, 274:6992-7001.
14. Phillips T., Jenkinson L., McCrae C., Thong B., Unitt J. Development of a high-throughput human rhinovirus infectivity cell-based assay for identifying antiviral compounds. J. Virol. Methods 2011, 173:182-188.
15. Puig-Basagoiti F., Deas T.S., Ren P., Tilgner M., Ferguson D.M., Shi P.Y. High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob. Agents Chemother. 2005, 49:4980-4988.
16. Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 1974, 129:304-309.
17. Schmidtke M., Schnittler U., Jahn B., Dahse H., Stelzner A. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J. Virol. Methods 2001, 95:133-143.
18. Shih S.R., Stollar V., Li M.L. Host factors in enterovirus 71 replication. J. Virol. 2011, 85:9658-9666.
19. Shimizu H., Agoh M., Agoh Y., Yoshida H., Yoshii K., Yoneyama T., Hagiwara A., Miyamura T. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 2000, 74:4146-4154.
20. Shum D., Smith J.L., Hirsch A.J., Bhinder B., Radu C., Stein D.A., Nelson J.A., Fruh K., Djaballah H. High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev. Technol. 2010, 8:553-570.
21. Song Y., Paul A.V., Wimmer E. Evolution of poliovirus defective interfering particles expressing Gaussia luciferase. J. Virol. 2012, 86:1999-2010.
22. Tan X., Huang X., Zhu S., Chen H., Yu Q., Wang H., Huo X., Zhou J., Wu Y., Yan D., Zhang Y., Wang D., Cui A., An H., Xu W. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS ONE 2011, 6:e25662.
23. Teterina N.L., Levenson E.A., Ehrenfeld E. Viable polioviruses that encode 2A proteins with fluorescent protein tags. J. Virol. 2010, 84:1477-1488.
24. Teterina N.L., Lauber C., Jensen K.S., Levenson E.A., Gorbalenya A.E., Ehrenfeld E. Identification of tolerated insertion sites in poliovirus non-structural proteins. Virology 2011, 409:1-11.
25. Teterina N.L., Pinto Y., Weaver J.D., Jensen K.S., Ehrenfeld E. Analysis of poliovirus protein 3A interactions with viral and cellular proteins in infected cells. J. Virol. 2011, 85:4284-4296.
26. Thibaut H.J., De Palma A.M., Neyts J. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 2012, 83:185-192.
27. Tsai M.T., Cheng Y.H., Liu Y.N., Liao N.C., Lu W.W., Kung S.H. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob. Agents Chemother. 2009, 53:748-755.
28. Wu K.X., Ng M.M., Chu J.J. Developments towards antiviral therapies against enterovirus 71. Drug Discov. Today 2010, 15:1041-1051.
29. Zhang B., Dong H., Ye H., Tilgner M., Shi P.Y. Genetic analysis of West Nile virus containing a complete 3'CSI RNA deletion. Virology 2010, 408:138-145.